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During mammalian ontogenesis, the neurotransmitter GABA is a fundamental regulator
of neuronal networks. In neuronal development, GABAergic signaling regulates neural
proliferation, migration, differentiation, and neuronal-network wiring. In the adult, GABA
orchestrates the activity of different neuronal cell-types largely interconnected, by
powerfully modulating synaptic activity. GABA exerts these functions by binding to
chloride-permeable ionotropic GABAA receptors and metabotropic GABAB receptors.
According to its functional importance during development, GABA is implicated in a
number of neurodevelopmental disorders such as autism, Fragile X, Rett syndrome,
Down syndrome, schizophrenia, Tourette’s syndrome and neurofibromatosis. The strength
and polarity of GABAergic transmission is continuously modulated during physiological,
but also pathological conditions. For GABAergic transmission through GABAA receptors,
strength regulation is achieved by different mechanisms such as modulation of GABAA
receptors themselves, variation of intracellular chloride concentration, and alteration in
GABA metabolism. In the never-ending effort to find possible treatments for GABA-related
neurological diseases, of great importance would be modulating GABAergic transmission
in a safe and possibly physiological way, without the dangers of either silencing network
activity or causing epileptic seizures. In this review, we will discuss the different ways
to modulate GABAergic transmission normally at work both during physiological and
pathological conditions. Our aim is to highlight new research perspectives for therapeutic
treatments that reinstate natural and physiological brain functions in neuro-pathological
conditions.
Keywords: GABA, neurodevelopmental disorders, cation chloride cotransporters, GABAA receptor, GABA
metabolism
INTRODUCTION
Gamma-aminobutyric acid (GABA) is the main inhibitory
neurotransmitter in the mature brain by mainly binding to chlo-
ride (Cl−) and bicarbonate (HCO−3 )-permeable GABAA recep-
tors (GABAAR; Mohler, 2007; Hubner and Holthoff, 2013) and
metabotropic GABAB receptors. The regulation of neuronal activ-
ity by GABA depends on its metabolism, expression and activity
of the pre- and postsynaptic receptors, and on the electrochemical
gradient of Cl− across the cellular membrane.
GABA is synthesized from glutamate as a substrate by two
glutamic acid decarboxylase enzymes (GAD) of different molec-
ular weight: GAD67 and GAD65 (encoded by the Gad1 and
Gad2 genes, respectively; Pinal and Tobin, 1998). The two iso-
forms show striking differences in their developmental expression
(Kiser et al., 1998; Buddhala et al., 2009), subcellular localiza-
tion (Dupuy and Houser, 1996; Buddhala et al., 2009), enzymatic
activity (Battaglioli et al., 2003; Fenalti et al., 2007), and gene reg-
ulation (Feldblum et al., 1993; Pinal and Tobin, 1998; Buddhala
et al., 2009). In particular, GAD67 has a cytosolic localization
mostly in the neuronal soma, and it provides basal level of
GABA synthesis. Conversely, GAD65 is preferentially located in
the axonal terminal and it provides additional supply of GABA in
condition of metabolic demand (Asada et al., 1997; Kash et al.,
1997; Namchuk et al., 1997; Buddhala et al., 2009).
Once synthesized, vesicular GABA transporters (VGATs),
which are embedded in presynaptic vesicular membranes, use
the electrochemical gradient for H+ to shuffle and pack GABA
into small synaptic vesicles (Roth et al., 2012). Upon fusion
of the synaptic vesicles to the cell membrane due to incoming
action potentials, GABA is released in the synaptic cleft where it
acts on ionotropic GABAA and GABAC, as well as metabotropic
GABAB receptors. The magnitude and direction of the ionic cur-
rent through GABAARs exquisitely depends on its driving force,
defined as the difference between the electrochemical equilib-
rium potential of Cl− anions (reversal potential, ECl) and the
resting membrane potential of the neuron (Vm). If this dif-
ference is positive or negative, there will be a net flux of Cl−
anions through the plasma membrane following GABAAR open-
ing, and this will result in a change in the membrane potential
of the neuron. In particular, the net flux of Cl− anions through
GABAAR (i.e., toward inside or outside the cell) critically hinges
on its intracellular concentration ([Cl−]i). In neurons, two main
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chloride cotransporters are responsible for setting [Cl−]i. The
Na+/K+/Cl− cotransporter NKCC1 (Blaesse et al., 2009), which
imports Cl− into the neuron, and the K+/Cl− cotransporter
KCC2, which exports Cl− out of the neuron (Rivera et al.,
1999; Sernagor et al., 2010; Kahle et al., 2013). When ECl is
close to Vm, GABA will exert its inhibitory action by a shunting
inhibitory mechanism. Indeed, the local increase in membrane
GABAAR conductance will “hold” the neuron at the ECl, reducing
the amplitude of subsequent excitatory postsynaptic potentials
(following Ohm’s law) and thus shunting any excitatory input
(Gonzalez-Burgos et al., 2011).
The termination of GABA action at synapses depends on
GABA reuptake into nerve terminals and astrocytes by GABA
transporters located at the cell membrane (GATs; Lee et al.,
2006b). Finally, the catabolism of GABA depends on the action
of GABA transaminase enzyme (GABA-T) and succinate semi-
aldehyde dehydrogenase enzyme (SSADH), which convert GABA
into intermediates of the Krebs cycle and substrates for new
production of glutamate.
During early development, GABA is depolarizing and mostly
excitatory due to high [Cl−]i, and it plays a key role by regulat-
ing a number of processes including migration, morphological
maturation and differentiation of neurons (Ben-Ari et al., 2007;
Wang and Kriegstein, 2009; Ben-Ari et al., 2012). Accordingly,
GABAergic signaling has been implicated in a number of neu-
rodevelopmental disorders, such as autism (Tabuchi et al., 2007;
Coghlan et al., 2012), Fragile X (Curia et al., 2009; Coghlan
et al., 2012), Rett Syndrome (Medrihan et al., 2008; Coghlan
et al., 2012), Down Syndrome (Chakrabarti et al., 2010; Costa
and Scott-McKean, 2013), Schizophrenia (Lewis et al., 2012),
Tourette Syndrome (Kalanithi et al., 2005; Di Cristo, 2007), and
Neurofibromatosis type I (Costa et al., 2002; Diggs-Andrews
and Gutmann, 2013). Unfortunately, in most cases GABAergic
drugs are dangerous because either they silence the neuronal
network activity in a developing brain or, more often, they
trigger epilepsy in patients with neurodevelopmental disor-
ders, who -similarly to infants- (Connell et al., 1989; Sankar
and Painter, 2005; Briggs and Galanopoulou, 2011; Loscher
et al., 2013) are at higher risk of seizures per se (Rissman and
Mobley, 2011; Coghlan et al., 2012; Ostendorf et al., 2013;
Williams et al., 2013). Finding viable therapeutic treatments
targeting GABAergic transmission in neurodevelopmental dis-
orders is thus both of great importance and a big challenge.
Addressing this issue implies the study of the fine modulation
of GABAergic transmission during physiological conditions as
a starting point to tackle dysfunctional transmission in neu-
rodevelopmental disorders. The overall goal of such a chal-
lenging approach is to find a physiologically subtler way to
safely modulate GABAergic signaling without hurting the deli-
cate equilibrium of the neuronal-network activity in a developing
brain.
In the first part of this review, we will discuss different ways
to modulate GABAergic transmission naturally at work during
physiological conditions. In the second part, we will discuss how
GABAergic transmission is affected in disease, and we will give
examples of therapeutic approaches that are currently utilized to
reinstate brain functions in neuro-pathological conditions.
MODULATION OF GABAergic TRANSMISSION UNDER
NORMAL PHYSIOLOGICAL CONDITIONS
Modulation of GABAergic transmission is achieved under differ-
ent physiological conditions in the brain in diverse ways, rang-
ing from regulation of GABAAR expression/activity and GABA
metabolism to regulation of intracellular chloride concentration.
MODULATION OF GABAA RECEPTOR FUNCTION
GABAARs are composed of 5 protein subunits belonging to 19
different classes (α1–6, β1–3, γ1–3, δ, , θ, π, ρ1–3; Simon et al.,
2004; Luscher et al., 2011; Hubner and Holthoff, 2013; Fritschy
and Panzanelli, 2014). The assembly of GABAARs as heteropen-
tamers produces complex heterogeneity in their structure, which
is the major determinant of their pharmacological profile and
kinetics (Barnard et al., 1998; Luscher et al., 2011; Fritschy and
Panzanelli, 2014). In adult mammals, the most common config-
uration at the synapse comprises two α1, two β2, and one γ2 sub-
units. This composition guarantees fast and short-lasting (phasic)
inhibition mediated by fast desensitizing postsynaptic receptors.
Interestingly, GABAAR composition changes during ontogenesis,
in order to meet the needs of continuously developing neuronal
networks. During early development, when synaptogenesis is not
fully established, GABA signaling through GABAARs is mainly
achieved at extra synapticsites. Extrasynaptic GABAARs contain
α5 or δ, as well as β2/3 and γ subunits, allowing “ambient”
GABA to elicit long-lasting (tonic) currents that result in per-
sistent depolarization in young neurons (Cellot and Cherubini,
2013). This tonic activation of extrasynaptic GABAARs is critical
at that time, as it regulates cell migration, proliferation, neurite
growth and synapse formation (Ben-Ari et al., 2007; Wang and
Kriegstein, 2009). Interestingly, when synaptogenesis begins, α5
subunits are downregulated and its neuronal localization switches
from the soma to the dendritic compartment in the hippocampus
(Ramos et al., 2004).
Upon the establishment of structural synapses, functional
communication between neurons requires GABAARs localized at
the synapses. At that time, the first formation of primitive func-
tional neuronal circuits follows the hebbian rule “neurons that
fire together wire together” (Ben-Ari et al., 2007). Consequently,
GABAAR kinetics are determined by the widespread distribution
of α2/3 subunits, which ensures long-lasting currents well-suited
for increasing probability of concurrent spiking from different
cells (Fritschy et al., 1994; Uusi-Oukari and Korpi, 2010). As
development progresses, α2 and α3 subunits are downregulated,
whereas α1 and α6 subunits are up-regulated (Laurie et al., 1992;
Poulter et al., 1992; Uusi-Oukari and Korpi, 2010). This results
in a faster decay time of GABAergic events, which allows precise
setting of the temporal window for synaptic integration (Pouille
and Scanziani, 2001) and synchronization of neuronal networks
(Cobb et al., 1995; Whittington et al., 2011). Of note, intracellu-
lar chloride itself has been recently shown to influence the subunit
composition, possibly acting as an intracellular messenger (Succol
et al., 2012).
Once perinatal development is completed, production of new
neurons in the adult (adult neurogenesis) remains restricted only
to certain brain niches in the dentate gyrus of the hippocam-
pus and in the olfactory bulb. Interestingly, adult neurogenesis is
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also under the control of GABAergic transmission (Fritschy and
Panzanelli, 2014). Not surprisingly, neurogenesis in early devel-
opment and in the adult share many similarities. For instance,
availability of different GABAAR subunits provides a molecu-
lar mechanism to precisely control neuronal maturation in the
dentate gyrus at spatio-temporal level. Indeed, neuronal pro-
genitors cells (NPCs) express functional GABAARs composed of
α5β3γ2 subunits mediating a tonic response to GABA that main-
tains NPCs in a quiescence state (Song et al., 2012). Interestingly,
mice lacking α4 subunits mediating GABAA tonic currents,
show increased proliferation and impaired dendritic matura-
tion at early stages. Remarkably, this effect is not present in the
mouse line lacking δ subunit, also mediating GABAA tonic cur-
rents (Duveau et al., 2011). Conversely, α2 subunit, mediating
GABAA phasic currents, controls positioning of newborn neurons
and dendritic maturation at later stages (Duveau et al., 2011).
In the olfactory bulb, specific GABAAR subunits also regulate
adult neurogenesis, as for example α2 subunit regulates neuronal
maturation (Pallotto et al., 2012).
Once neuronal circuits are established, and generation of new
neurons continues only in discrete niches, the developing brain
still retains the potential to learn and respond to experience with
plastic changes in neuronal connections. Again, brain plastic-
ity is finely regulated by GABAergic transmission (Fritschy and
Panzanelli, 2014). Long-term potentiation (LTP) is a long-lasting
increase in the synaptic efficacy elicited by reliable experimen-
tal protocols of short, high-frequency stimulation of presynaptic
fibers, and it is thus considered as an established model of learn-
ing and brain plasticity (Bliss and Collingridge, 1993; Feldman,
2009, 2012). LTP can be easily induced in different regions of the
brain (Feldman, 2009, 2012), and in all these structures, GABAAR
activity prevents or reduces LTP magnitude in vitro (Wigstrom
and Gustafsson, 1983; Grover and Yan, 1999; Kleschevnikov
et al., 2004; Harauzov et al., 2010; Arima-Yoshida et al., 2011;
Contestabile et al., 2013) and in vivo (Hirai and Okada, 1993;
Kaibara and Leung, 1993; Matsuyama et al., 2008; Feldman,
2012). In particular, in the visual cortex, the peculiar contribution
of GABAAR signaling on LTP depends on the so-called “critical
period,” a process of experience-dependent maturation during
a specific temporal window after birth. Only during the criti-
cal period, but not in the adult, it is possible to induce LTP and
another paradigm of plasticity in vivo called monocular depriva-
tion (MD), consisting of a functional and an anatomical plastic
rearrangement of visual neuronal circuits after a brief period of
sight deprivation in one eye (Hensch, 2004; Levelt and Hubener,
2012). Interestingly, GABA controls both the opening and the
closure of critical period for plasticity paradigms LTP and MD
(Heimel et al., 2011; Levelt and Hubener, 2012). Importantly,
critical-period plasticity depends on specific GABAARs subunits,
as demonstrated by the finding that only neuronal circuits con-
taining α1 GABAAR subunits drive cortical plasticity (Fagiolini
et al., 2004; Fritschy and Panzanelli, 2014).
One important mechanism regulating trafficking of GABAARs
as well as their kinetics is phosphorylation of specific α, β,
and γ subunits by diverse serine/threonine or tyrosine kinases
(Kittler and Moss, 2003; Vithlani et al., 2011). In particu-
lar, α4 phosphorylation by protein kinase C (PKC) increases
insertion and stability of α4/β3-containing GABAAR (Abramian
et al., 2010), but also decreases surface expression and activity
of α4/β2/δ containing receptors, possibly suggesting that their
differential regulation could be due to the expression of dif-
ferent β subunits (Bright and Smart, 2013). Moreover, phos-
phorylation of β1 subunit by cAMP-dependent kinase (PKA)
decreases GABA currents, whereas β2 subunit does not respond
to PKA (Brandon et al., 2002; Kittler and Moss, 2003). On the
other hand, β2 subunit can be phosphorylated by Akt increas-
ing postsynaptic GABAAR expression (Wang et al., 2003c) and
by calcium/calmodulin-dependent protein kinase II (CaMKII)
increasing the amplitude of spontaneous inhibitory postsynaptic
currents (IPSC; Houston et al., 2008). Conversely, when phospho-
rylating the β3 subunit, CaMKII increases the decay time of sIP-
SCs (Houston et al., 2008), but also increases surface expression of
α5/β3-containing receptors and tonic currents in different exper-
imental systems (Saliba et al., 2012). Moreover, phosphorylation
of the β3 subunit by PKA increases GABA currents (McDonald
et al., 1998; Brandon et al., 2002). Lastly, phosphorylation of the
γ2 subunit decreases the internalization rate of GABAARs and
therefore increases their surface expression (Kittler et al., 2008).
Some GABAAR subunits are basally phosphorylated (Brandon
et al., 2000, 2001), and some phosphatases dephosphorylate spe-
cific subunits (Jones and Westbrook, 1997; Huang and Dillon,
1998; Lu et al., 2000; Wang et al., 2003b; Jovanovic et al.,
2004; Terunuma et al., 2004; Muir et al., 2010). This sug-
gests that physiological modulation of the phosphorylation state
of GABAARs is finely tuned and may regulate their function.
Specifically, protein phosphatases 1α and 2A (but not 2B, i.e.,
calcineurin) dephosphorylate the β3 subunit of the GABAAR,
leading to decrease of mIPSC amplitude in hippocampal neu-
rons (Jovanovic et al., 2004; Terunuma et al., 2004). On the
other hand, NMDA-dependent activation of calcineurin medi-
ates long-term depression (LTD) at inhibitory synapses through
γ2 subunit dephosphorylation and consequent reduction of
GABAAR responses (Lu et al., 2000; Wang et al., 2003b).
Possibly, GABAAR cluster dispersal is responsible for the reduc-
tion of GABAAR responses, given that NMDA-dependent activa-
tion of calcineurin and consequent GABAAR dephosphorylation
increases lateral diffusion of the receptor itself (Muir et al., 2010).
The efficacy of GABAAergic transmission is also determined
by the number of GABAARs at the synaptic site. As this depends
on the rates of insertion and removal of the receptor themselves,
endocytosis and rapid recycling (Kittler et al., 2000) or ubiquitin-
dependent degradation of GABAARs (Saliba et al., 2007) can
also modify the efficacy of postsynaptic inhibition. Accordingly,
changes in lateral diffusion of GABAARs inside and outside of the
synapse, may play a major role in the regulation of GABAAergic
synaptic transmission (Triller and Choquet, 2005). Indeed, as
described for glutamate receptors (Heine et al., 2008; Petrini et al.,
2009), rapid exchange of desensitized receptors between synaptic
and extrasynaptic site could allow a higher current to flow at the
postsynaptic site.
MODULATION OF GABA METABOLISM
Modulation of GABAergic signaling can also occur at metabolic
level, including both anabolism and catabolism of GABA.
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GAD enzymes synthetize GABA and they are differentially
expressed during ontogenesis, probably reflecting diverse contri-
butions to GABAergic regulation of brain activity. GAD65 and
GAD67 are mainly expressed during postnatal development and
in the mature brain, whereas two truncated forms of GAD67
(GAD25 and GAD44) are mainly expressed during embryonic
development (Buddhala et al., 2009). GAD25 represents the
regulatory amino-terminal domain of GAD67, whereas GAD44
represents the enzymatic carboxy-terminal. Although the role of
GAD25 and GAD44 during embryonic development has not been
understood yet, their expression -at a time when cell prolifera-
tion, migration and synaptogenesis occur- has suggested that they
could play a role in these processes (Popp et al., 2009). As devel-
opment progresses, GAD25 and GAD44 expression diminishes
accompanied by an increased expression of the active forms of
GAD -GAD65 and GAD67- and a concomitant increase of GABA
synthesis (Varju et al., 2002).
In particular, GAD67 is expressed earlier than GAD65 (Kiser
et al., 1998), it is ubiquitously present in the neuron (Esclapez
et al., 1994), and it is expressed as a permanently active enzyme
(Lindefors, 1993). Conversely, GAD65 is expressed later than
GAD67 (Kiser et al., 1998), it preferentially localizes at synap-
tic terminals (Esclapez et al., 1994), and it is largely present
as an inactive apoenzyme, which can be activated by neuronal
activity (Lindefors, 1993; Buddhala et al., 2009). Thus, GAD65
and GAD67 seem to provide a dual system for the control of
GABAergic transmission: at earlier stages, GAD67 contributes to
tonic GABA transmission necessary for proper development of
neuronal circuits (Kaufman et al., 1991; Esclapez et al., 1994).
In line with this, GAD67 knockout (KO) mice, which exhibit
a 93% reduction of GABA levels, die perinatally (Asada et al.,
1997). Once circuits are established (but still immature), GAD65
is expressed and implicated in sustained phasic synaptic transmis-
sion in response to neuronal activity (Hensch et al., 1998; Tian
et al., 1999; Buddhala et al., 2009). This phasic synaptic trans-
mission supports GABA in reaching a threshold level necessary
to render neuronal circuit responsive to experience by functional
and anatomical plastic shaping (Fagiolini and Hensch, 2000;
Heimel et al., 2011; Levelt and Hubener, 2012). Indeed, GAD65
KO mice are profoundly affected in their ability to respond to
monocular deprivation (Hensch et al., 1998).
GABA vesicular transporters (VGAT) mediate transport of
GABA into small presynaptic vesicles. Interestingly, absence of
VGAT causes embryonic lethality in VGAT KO mice, indicating
a fundamental role for GABA release from synaptic vesicles in
brain development (Wojcik et al., 2006). Based on the increased
expression of VGAT during development, which parallels the
developmental switch of GABAergic responses from excitatory
to inhibitory, it was proposed that VGAT may also play a role
in regulating the latter switch. Nevertheless, the lack of a differ-
ence between the expression of KCC2 in VGAT KO in comparison
to wild type mice, seems to rule out this hypothesis (Wojcik
et al., 2006; Boulland and Chaudhry, 2012). On the other hand,
VGAT could still regulate the strength of presynaptic GABAAergic
transmission acutely (Kullmann et al., 2005), as in vitro experi-
ments show that VGAT co-transports Cl− anions together with
GABA (Juge et al., 2009), probably rendering [Cl−]i lower in the
presynaptic terminal. Finally, VGAT promotes GABAergic trans-
mission also indirectly by promoting GABA synthesis. Indeed,
VGAT forms a complex with GAD65 in the nerve terminal, and
its absence in the VGAT KO mice results in a loss of GAD65
itself from the presynaptic terminal (Jin et al., 2003; Wojcik et al.,
2006).
The control of GABA release represents another key step in the
regulation of GABAergic transmission. In this respect, an inter-
esting phenomenon is represented by kainate receptors (KARs),
which are expressed at presynaptic terminals of GABAergic
interneurons. Activation of these receptors results in a decrease in
the amplitude of GABAergic currents and a disinhibition of the
postsynaptic neuron (Sihra and Rodriguez-Moreno, 2011). Also
extracellular-signal-regulated kinases (ERK) can modulate GABA
release during neuronal activity (Cui et al., 2008). Moreover, non-
vesicular GABA release (i.e., via reversal of GAT-1), contributing
to GABA phasic transmission (Wu et al., 2007), can be stimulated
by nitric oxide (Tarasenko et al., 2014).
Once GABA is released, GABA transporters at the cell mem-
brane of axon terminals are responsible for GABA removal from
the synaptic cleft. GATs modulate GABAergic transmission by
regulating the time course of both phasic and tonic GABAergic
responses. Even if diffusion of GABA out of the synaptic cleft
is the primary determinant for the termination of the response,
GABA-uptake inhibitors greatly prolong the phasic conductance
associated with application of GABA, pointing to the role of
GATs in the termination of GABA-evoked postsynaptic poten-
tials (Dingledine and Korn, 1985; Zhou and Danbolt, 2013).
Moreover, GABA uptake becomes of primary importance in
conditions of sustained phasic activity of GABAergic neurons
(Kersante et al., 2013). On the other hand, GAT regulation
is fundamental also for tonic inhibition, as this requires con-
tinuous receptor activity elicited by ambient GABA. Indeed,
blockade of GABA uptake by GABA transporter blocker NO711
unmasks tonic inhibition in pyramidal neurons in the hippocam-
pus (Semyanov et al., 2003; Walker and Semyanov, 2008). Thus,
far, four GATs (GAT-1, GAT-2, GAT-3, BGT-1) have been iso-
lated (Roth and Draguhn, 2012; Zhou and Danbolt, 2013). As for
the different GAD isoforms, GATs are differently expressed dur-
ing development, possibly reflecting diverse needs of dynamically
developing neuronal networks. For example, during develop-
ment, GAT-3 is the mostly expressed in neurons, GAT-2 is poorly
expressed, and GAT-1 expression increases gradually (Minelli
et al., 1995; Evans et al., 1996; Zhou and Danbolt, 2013). As a
result, GAT-1 is the most abundant GAT isoform expressed in
neuronal and in astrocytic terminals and GAT-3 is expressed only
in astrocytes in the adult cortex (Evans et al., 1996). How the
expression of different GATs at diverse time of development and
in different cell types may influence GABAergic transmission still
needs to be elucidated.
REGULATION OF CATION/CHLORIDE COTRANSPORTERS
Modulation of GABAergic transmission by variation in [Cl−]i is a
mechanism naturally at work under a number or circumstances.
Interestingly, as Cl− reversal potential (ECl) rests very close to
the resting membrane potential of the neuron (Vm), even small
changes in [Cl−]i can result in significant shifts of the ECl, for
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instance from hyperpolarizing to depolarizing. The most char-
acterized example of modulation of GABAergic transmission by
variations in [Cl−]i occurs during ontogenesis. Indeed, a progres-
sive decrease of [Cl−]i is responsible for the shift of the polarity
of GABAergic transmission from depolarizing and mostly excita-
tory during early development to hyperpolarizing and inhibitory
in the adult. This developmental shift of GABAergic signaling has
been evolutionarily conserved from reptiles to humans, and it
possibly provides excitation in the developing brain without the
risk of glutamatergic excitotoxicity (Ben-Ari, 2002). Interestingly,
this switch also occurs during adult neurogenesis in the dentate
gyrus of the hippocampus and in the olfactory bulb (Wang et al.,
2003a; Ge et al., 2006, 2008; Sernagor et al., 2010; Young et al.,
2010; Ming and Song, 2011; Young et al., 2012).
The higher [Cl−]i in young neurons depends on high expres-
sion of NKCC1 (Dzhala et al., 2005), and it results in depolarizing
GABAA transmission. As development proceeds, KCC2 becomes
expressed at higher levels than NKCC1 (Rivera et al., 1999; Dzhala
et al., 2005), and hyperpolarizing GABAergic transmission takes
over (Ben-Ari, 2002; Ben-Ari et al., 2007; Cancedda et al., 2007;
Wang and Kriegstein, 2009; Sernagor et al., 2010). Of note, the
functional maturation of GABAAR signaling from depolariz-
ing to hyperpolarizing occurs earlier in females than in males
(Galanopoulou, 2008), mostly due to the different sex-related
expression of NKCC1 and KCC2 (Nunez and McCarthy, 2007).
Another example of how plasticity of ECl controls GABAergic
transmission and brain function under particular physiologi-
cal circumstances is in the regulation of the circadian rhythm.
Mammals, as many other species, entrain their behavior and hor-
monal daily oscillations to the internal biological clock, which
is hierarchically mastered by neurons in the suprachiasmatic
nucleus (SCN) of the hypothalamus (Lehman et al., 1987).
Interestingly, ECl undergoes changes during the circadian rhythm
in the SCN, although the effective polarity of GABAAergic trans-
mission is still controversial. Indeed, while first studies suggested
GABA to be excitatory at night and inhibitory during the day
(Liou and Albers, 1990; Bos and Mirmiran, 1993), a later study
revealed opposite actions (Wagner et al., 1997). Possibly, the dis-
crepancy between the two sets of results originated from the
use of diverse experimental conditions during the extracellular-
spike recordings (i.e., standard ACSF extracellular solution vs.
solutions modified in chloride concentration) to assess the polar-
ity of GABAA responses. To resolve this controversy, De Jeu
and coworkers directly measured ECl by means of gramicidin-
perforated patch-clamp recordings, which allow preservation of
[Cl−]i and, consequently, a correct assessment of the polarity of
GABAA responses (De Jeu and Pennartz, 2002). They found a
significant day vs. night difference in ECl with more depolarized
values during the night than during the day. In line with this, suc-
cessive studies showed that NKCC1 expression was higher at night
(Choi et al., 2008). Importantly, the excitatory effect of GABA
was reduced by application of NKCC1-inhibitor and loop diuretic
bumetanide in brain slices, and absent in Nkcc1 knock-out mice.
This points to a regulation of NKCC1 expression to achieve plas-
ticity of ECl during the circadian rhythm. This mechanism was
proposed to counteract propagation of excitatory signals during
the day (Choi et al., 2008).
Another example of modulation of GABAAergic transmission
through cation/chloride cotransporters during a particular phys-
iological condition is the shift in ECl during labor. Birth is a
stressful event associated with high risk of injury for the fetal
brain, and hypoxic-ischemic brain damage is one of the principal
causes of death and neurological impairment in infants (Volpe,
2008). Neuronal activity requires a high metabolic demand since
action-potential generation and propagation consumes 47% of
available ATP in neurons, while postsynaptic potentials consume
another 34% (Attwell and Laughlin, 2001). Consequently, as neu-
ronal activity cannot be easily sustained in condition of hypoxia,
the presence of a depolarizing action of GABAergic transmission
during delivery could further limit availability of energy sup-
ply caused by delivery-induced hypoxia, as experiments on high
neuronal activity during seizures would suggest (Dzhala et al.,
2000). In a very interesting study, Tyzio and co-workers investi-
gated whether activity of cation/chloride cotransporters during
delivery may be altered (Tyzio et al., 2006). They found a shift
of ECl to hyperpolarizing GABA responses 1–2 h before deliv-
ery. Interestingly, authors also found that bath application of
oxytocin, which is massively released before delivery to induce
parturition (Gimpl and Fahrenholz, 2001), suppressed GABA-
mediated excitation and induced a negative shift in ECl in slices
from animals 2 days before delivery. Finally, authors demon-
strated that oxytocin-mediated effect occurred via inhibition of
NKCC1 chloride cotransporter by treatment with bumetanide
(Tyzio et al., 2006).
Delivery is also potentially painful for the newborn (Fitzgerald,
2005), possibly leading to long-term pathological consequences
(Volpe, 2008, 2009). In a follow up study, Mazzuca and cowork-
ers demonstrated that oxytocin exerts an analgesic action against
pain in newborn rat pups, assessed in terms of thermal tail-flick
test and pain-induced vocalization. Also in this case, the effect
of oxytocin was achieved by a reduction of GABA depolariza-
tion via inhibition of NKCC1, as bumetanide recapitulated the
analgesic effects of oxytocin (Mazzuca et al., 2011). These find-
ings are in line with studies in humans indicating that infants
born by elective caesarean (c-) section show a lower threshold
for pain in comparison to infants born by natural vaginal deliv-
ery (Bergqvist et al., 2009), possibly due to the lack of release
of maternal oxytocin during delivery by c-section (Gimpl and
Fahrenholz, 2001).
The subtle modulation of GABAergic transmission through
cation/chloride cotransporters in condition of limiting energy
supply finds another example in the animal kingdom (Tyzio et al.,
2006). As mentioned above, neuronal activity requires a high
metabolic demand and it cannot be easily sustained in condi-
tion of hypoxia (Attwell and Laughlin, 2001). The pond snail
Lymnae stagnalis is a bimodal breather that can use cutaneous
gas exchange under well-oxygenated water, and lung exchange in
the air atmosphere in hypoxic condition, which naturally encoun-
ters during summer time when the pond water where it lives
dries out (Jones, 1961). Remarkably, the pond snail is able to sur-
vive under harsh hypoxic experimental conditions such as 40 h
in a N2-bubbled environment (Inoue et al., 2001). This is due
to a decrease in neuronal activity mediated by a switch in GABA
polarity under hypoxic conditions, and it promotes survival by
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reducing the energetic demand of the brain (Cheung et al., 2006).
Indeed, in normal conditions, GABA exerts an excitatory action in
the dorsal ganglia of the pond snail, which helps in maintaining
basal levels of spontaneous neuronal activity. Conversely, under
hypoxic condition, neurons become less active, an effect mim-
icked by inhibition of NKCC1 activity with bath application of
bumetanide.
Modulation of GABAergic transmission by regulation of
cation/chloride cotransporters also occurs at synaptic level. For
example, an activity-induced depolarizing shift in ECl has been
described after repetitive postsynaptic spiking (Fiumelli et al.,
2005), tetanic stimulation (Kaila et al., 1997), correlated synaptic
activity (Woodin et al., 2003), and rebound burst activity (Wang
et al., 2006a). Moreover, some evidence also suggests a role for
cation/chloride cotransporters in LTP, although with contrasting
results. In particular, while some authors report that following
high-frequency stimulation and LTP induction there is a down-
regulation of KCC2, pointing to a more depolarized ECl (Wang
et al., 2006b), other studies indicate that LTP induction results in
a shift in ECl toward more hyperpolarized values (Xu and Sastry,
2007). Of note, in one study, authors found that chloride chan-
nel CLC-3 contributes to reducing LTP magnitude, as CLC-3 KO
mice show an excessive induction of LTP (Farmer et al., 2013).
In agreement with the studies described above, in the presence
of increased neuronal activity driven by physiological sensory
stimulation, the brain responds also modulating the plasticity
of ECl by changes in cation/chloride cotransporters. For exam-
ple, environmental enrichment (EE), which is a combination
of inanimate and social stimuli providing a complex sensory-
motor stimulation (Rosenzweig et al., 1978; Sale et al., 2014),
promotes a precocious maturation of GABAergic transmission
in the visual system (Cancedda et al., 2004; Heimel et al., 2011;
Levelt and Hubener, 2012). Interestingly, this precocious matura-
tion is accompanied by an accelerated transition of GABA action
from depolarizing to hyperpolarizing, possibly due to a concomi-
tant increased expression of KCC2 (He et al., 2010). Finally, recent
studies reveal that also maternal deprivation can affect ECl, deter-
mining a negative shift of GABA responses. This effect seems
to be mediated by a higher expression of KCC2 cotransporter
(Galanopoulou, 2008). Thus, the plasticity of ECl plays a major
role in regulating naturally relevant behaviors.
MODULATION OF GABAERGIC TRANSMISSION IN
PATHOLOGY AND THERAPEUTIC PERSPECTIVES
Given the pivotal role of GABA in the regulation of brain develop-
ment and functioning, it is not surprising that alterations in the
GABAergic system have been implicated in a number of neurode-
velopmental disorders (Di Cristo et al., 2011). As we described
above for the modulation of GABAergic signaling in physiology,
the alterations of the GABAergic system in neurodevelopmental
disorders can occur at the level of GABA receptors, metabolism
and/or cation/chloride cotransporters (Table 1).
AUTISM SPECTRUM DISORDERS
Autism spectrum disorders (ASDs) are a group of syndromes of
diverse etiology with a common set of core symptoms that include
compromised social interaction, impaired communication, and
repetitive behaviors (Pizzarelli and Cherubini, 2011). ASDs can
be idiopathic or co-morbid with other syndromes such as Fragile
X or Rett syndrome. Notwithstanding the wide variation in
the etiology, the consistency in symptomatology suggests that
the mechanisms underlying the pathology of ASDs are com-
mon. Mounting evidence indicates that one such mechanism
is an impairment in the neuronal excitatory/inhibitory balance
(Pizzarelli and Cherubini, 2011), as also suggested by the high
prevalence of epilepsy in patients with ASDs (Brooks-Kayal,
2010). Accordingly, several studies have identified mutations in
different GABAAR subunits as risk factors for the development
of ASDs (Coghlan et al., 2012) and autism-related genes have
been found to be mostly expressed in interneurons (Xu et al.,
2014). In particular, GABRB3, GABRA5, and GABRG3 genes
were described as risk factors (Cook et al., 1998; Menold et al.,
2001; Buxbaum et al., 2002; Shao et al., 2003; McCauley et al.,
2004), and GABRA4 was found to be involved in ASD on its
own, but also through interaction with GABRB1 (Ma et al.,
2005). Moreover, GABAAR subunits α1–5, β1 and β3 and GAD65
and 67 are downregulated in autistic brains (Fatemi et al., 2002,
2009, 2010; Mendez et al., 2013). Accordingly, GABA levels are
decreased in the frontal lobe and in the auditory cortex of autis-
tic patients (Harada et al., 2011; Rojas et al., 2013). In addition,
mutations in interneuron-associated genes DLX1 and DLX2 have
been described as susceptibility factors for ASD. Finally, benzo-
diazepine binding to GABAARs is decreased in the hippocampus
and frontal cortex of ASD patients (Blatt et al., 2001; Guptill et al.,
2007; Liu et al., 2009; Mori et al., 2012).
Benzodiazepines have been used to treat autistic patients
along with other antiepileptic drugs (AEDs), mostly because
of the comorbidity of ASD and epilepsy. Interestingly, it was
proposed that antiepileptics might have an effect on modulat-
ing behavioral aspects, as in some studies antiepileptic drugs
improved socialization and communication skills (Di Martino
and Tuchman, 2001). Nevertheless, consensus on this issue
has not been reached yet. In fact, a study by Marrosu and
coworkers showed that the use of diazepam had a paradoxical
effect by increasing anxiety and aggression in autistic children
(Marrosu et al., 1987). This observation led to the hypothesis
that GABA could be having excitatory actions in ASD, result-
ing in a groundbreaking pilot study to test the therapeutical
actions of chronic bumetanide treatment in ASD children. By
inhibition of NKCC1, the treatment was designed to revert the
polarity of GABAergic response from possibly depolarizing to
hyperpolarizing in autistic children (Lemonnier and Ben-Ari,
2010). The reduction in autistic scores and the absence of side
effects over 3 months of treatment in 5 autistic children led
the research group to perform a larger and double-blind clin-
ical trial with 54 patients (Lemonnier et al., 2012). After 3
months of treatment, patients showed a significant amelioration
of their symptoms. In addition, this effect was still noticeable
(although to a lesser degree) after a 1 month wash-out period.
Finally, the same group has recently showed that adolescents and
young adults show improvement in emotion recognition after 10
months of treatment with bumetanide (Hadjikhani et al., 2013).
Interestingly, an abolished GABA excitatory-inhibitory shift dur-
ing delivery leading to a chronic deficient chloride regulation and
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Table 1 | Summary of GABAA signaling alterations in neurodevelopmental disorders.
Disorder Main animal model(s) GABA transmission deficits and
therapeutic approaches (animal
models)
GABA transmission deficits
(human patients)
Selected references
Autism
spectrum
disorders
15q11–13 duplication
mice
Increased gene expression of α5,
β3, and γ3 subunits
Dysregulation of interneuron
genes
GABAA receptor expression
abnormalities (usually
downregulation)
Higher epilepsy rates
Improvement of autistic scores
after bumetanide treatment
Planned clinical trials with GABAA
agonist AZ7325
(http://clinicaltrials.gov/;
NCT01966679)
Fatemi et al., 2009, 2010; Liu
et al., 2009; Nakatani et al., 2009;
Brooks-Kayal, 2010; Penagarikano
et al., 2011; Lemonnier et al.,
2012; Hadjikhani et al., 2013; Han
et al., 2014; Tyzio et al., 2014
CNTNAP2 KO mice Decreased GABAergic
interneurons
Presence of seizures
BTBR T+ Itpr3tf /J
mice
Behavioral abnormalities rescued
by GABAA α2/α2 agonists
In utero valproate
exposed rats
Bumetanide treatment restores
aberrant electrophysiology and
vocalizations
Fragile X Fmr1 KO mice Decreased interneurons and
GABAA receptor gene expression
Hyper excitability in slices and
behavior including increased
seizure susceptibility which can
all be rescued by GABAA positive
modulators
Depolarizing GABAergic response
rescued by bumetanide
Increased prevalence of epilepsy
Improvement in autistic and
intellectual scores after
bumetanide treatment
GABAA allosteric modulator
Ganaxolone currently in clinical
trials (http://clinicaltrials.gov/;
NCT01725152)
D’Hulst et al., 2006; Selby et al.,
2007; Olmos-Serrano et al., 2010,
2011; Heulens et al., 2012;
Lemonnier et al., 2013; Tyzio
et al., 2014
Rett syndrome MECP2 KO mice Decrease in GAD65 and abnormal
interneuron-related gene
expression
Decreased inhibition in slices
Respiratory alterations that are
rescued by GABA agonists
GABAA receptor dysregulation
Epilepsy in 80% of
Breathing abnormalities patients
Yamashita et al., 1998; Blue et al.,
1999; Jian et al., 2006; Medrihan
et al., 2008; Voituron and Hilaire,
2011; Durand et al., 2012; Jin
et al., 2013
Down
syndrome
Ts65Dn mice Increased number of interneurons
Increased GABAergic signaling,
GAD65, GAD67, VGAT all rescued
by negative GABAA modulation
Decreased LTP and cognitive
behavioral tasks that can be
rescued by GABAA antagonists
Increased seizure susceptibility
Decreased GABA levels in fetuses
and in children
Increased seizure susceptibility
GABAA α5 inverse agonist
currently in clinical trials
(http://clinicaltrials.gov/;
NCT01436955,NCT02024789)
Pueschel et al., 1991; Fernandez
et al., 2007; Whittle et al., 2007;
Smigielska-Kuzia et al., 2010;
Westmark et al., 2010; Chakrabarti
et al., 2011; Rissman and Mobley,
2011; Kleschevnikov et al., 2012;
Martinez-Cue et al., 2013
Schizophrenia Non-genetic models:
PCP exposition
Chronic dopamine (D2)
receptor stimulation
Decreased GAD65 and GAD67,
GAT1 and α, β3, δ subunit mRNA
Decreased reelin and
interneurons
Deficits in GAD65 and GAD67 as
well as in reelin, interneurons,
GAT1 and multiple GABAA
receptor subunits
Wolkowitz and Pickar, 1991; Pierri
et al., 1999; Guidotti et al., 2000;
Cotter et al., 2002; Harte et al.,
2007; Hikida et al., 2007;
Hashimoto et al., 2008; Bullock
et al., 2009; Cassidy et al., 2010;
(Continued)
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Table 1 | Continued
Disorder Main animal model(s) GABA transmission deficits and
therapeutic approaches (animal
models)
GABA transmission deficits
(human patients)
Selected references
Social isolation Decreased pre-pulse inhibition Some patients respond well to
benzodiazepine treatment
Beneyto et al., 2011; Schmidt and
Mirnics, 2012; Del Pino et al.,
2013; Yu et al., 2013Genetic models:
DISC1 downregulation
Erbb4 downregulation
GAT1KO
Decreased parvalbumin cells
Decreased pre-pulse inhibition
Tourette
syndrome
Striatum injections of
GABAA antagonists in
rodents and primates
Induction of motor tics
resembling those of patients
Interneuron dysregulation
Abnormal GABAA receptor
binding
Increased epilepsy
Modest tic suppression
by GABA acting drugs
Kalanithi et al., 2005; McCairn
et al., 2009; Shprecher and
Kurlan, 2009; Worbe et al., 2009;
Kataoka et al., 2010;
Martinez-Granero et al., 2010;
Lerner et al., 2012; Bronfeld et al.,
2013; Williams et al., 2013
Neurofibro
matosis type 1
NF1 KO mice Increased GABAergic release and
transmission
Deficits in memory and LTP that
can be rescued by GABAA
antagonists
Decreased GABA levels
Increased epilepsy
Costa and Silva, 2002; Costa
et al., 2002; Cui et al., 2008;
Ostendorf et al., 2013; Violante
et al., 2013
autistic-like behaviors has been recently shown in the valproate
and fragile X rodent models of autism (Tyzio et al., 2014). Of
note, a planned clinical trial with a selective α2/3 selective ago-
nist (AZ7325) will recruit patients soon (http://clinicaltrials.gov/;
NCT01966679).
Reinforcing the hypothesis of an involvement of faulty
GABAergic transmission in autism, mice with 15q11-13 dupli-
cation and contactin-associated protein-like 2 (CNTNAP2) KO
mice -two mutations present in some autistic patients- present
autistic-like behaviors associated with increased α5, β3, γ3 subunit
mRNAs as well as decreased number of parvalbumin, calretinin
and neuropeptid Y interneurons, respectively (Nakatani et al.,
2009; Penagarikano et al., 2011). Further correlation between
compromised GABAergic transmission and ASD was found in a
mouse mutant of voltage-gated ion channels where the mutation
was restricted to forebrain interneurons. These animals exhibited
autistic behaviors (i.e., decreased social interaction) that were res-
cued by benzodiazepine treatment (Han et al., 2012). Moreover,
in the BTBR T+ Itpr3tf /J (a mouse strain that is used as a model
of idiopathic autism given its behavioral profile including poor
social interaction) low doses of a drug acting on α2/3 subunits
(i.e., L-838,417) ameliorate short- and long-term memory as well
as social interaction deficits (Han et al., 2014). Finally, the NHE9
gene which encodes a (Na+, K+)/H+ exchanger, is a genetic
factor that increases risk for ASD and could potentially affect
GABA activity by altering ionic gradients and consequent [Cl−]i
(Morrow et al., 2008).
FRAGILE X SYNDROME
Fragile X is a monogenic disorder caused by mutations in the
FMR1 gene (Bagni and Greenough, 2005). This gene encodes for
the Fragile X mental retardation protein (FMRP), which regu-
lates the translation of a wide array of mRNAs. As a considerable
amount of Fragile X patients show autistic symptoms and/or
comorbidity with epilepsy, neuronal excitatory/inhibitory imbal-
ance has been hypothesized also in these patients (Coghlan et al.,
2012). Accordingly, hyper excitability in slices has been described
in the Fmr1 KO mouse model (Gibson et al., 2008; Olmos-
Serrano et al., 2010; Paluszkiewicz et al., 2011; Goncalves et al.,
2013). In particular, recordings in these mice showed decreased
sIPSCs and mIPSCs as well as decreased tonic inhibition in the
amygdala, and increased firing rate and synchrony in the cor-
tex (Olmos-Serrano et al., 2010; Goncalves et al., 2013 but also
see Centonze et al., 2008). Interestingly, this hyperexcitability at
synaptic level was accompanied by hyperexcitability at behavioral
level, as demonstrated by increased activity in the open field. This
could be rescued by GABAA agonist THIP -which increases tonic
currents by mainly acting on the δ subunit- at doses that did not
have an effect on wild-type mice (Olmos-Serrano et al., 2011).
Among possible causes for the neuronal excitatory/inhibitory
imbalance in Fragile X, deficits at different levels of the
GABAergic signaling have been described. In particular,
decreased density of PV-expressing interneurons was described
in Fmr1 KO (Selby et al., 2007). Moreover, deficits in GABAAR
mRNA and protein levels for different subunits (i.e., α1, α3, α4,
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β1, β2, δ, γ1, and γ2) were reported in Fmr1 KO, although some
authors found these defects only during development (El Idrissi
et al., 2005; D’Hulst et al., 2006; Gantois et al., 2006; Adusei et al.,
2010). Besides downregulation of GABAAR subunits, also defects
in GABA metabolism have been described, as mRNA for GAD1
and protein expression of GAD65/67 was decreased in Fmr1 KO
mice (D’Hulst et al., 2009; Olmos-Serrano et al., 2010), although
these studies contrast with others that found GAD65/67 to be
increased in these mice (El Idrissi et al., 2005; Adusei et al., 2010).
Moreover, mRNA for GAT1 and 4, succinate semialdehyde dehy-
drogenase (SSADH) and GABA-T are decreased whereas GABA
release probability is increased in Fmr1 KOmice (Centonze et al.,
2008). Finally, gephyrin (a GABAergic postsynaptic marker)
expression is decreased in the cortex of these mice (D’Hulst et al.,
2009).
In line with the above findings hypothesizing a decrease in
GABAergic transmission in Fragile X, a number of in vivo stud-
ies attempted to rescue behavioral deficits in mouse models by
increasing GABAergic signaling. For example, administration of
GABAA agonist taurine rescued performance in the passive avoid-
ance task in Fmr1 KO mice (El Idrissi et al., 2009). Moreover,
hyperexcitability in slices and behavior in mice were rescued by
the agonist THIP (Olmos-Serrano et al., 2010, 2011). Recently,
treatment with diazepam or ganaxolone (a neurostreroid that
can positively modulate GABAARs) rescued audiogenic-induced
seizures in Fmr1 KO animals (Heulens et al., 2012). The fact
that the δ subunit is downregulated in Fmr1 KO mice and the
encouraging results with THIP and ganaxolone -both of which act
through the δ subunit- suggest that the δ subunit of the GABAAR
could be a good therapeutic target in Fragile X. Indeed, ganax-
olone is being tested in a Phase 2 clinical trial for children with
Fragile X (NCT01725152, http://clinicaltrials.gov/).
Finally, given their earlier success in treating autistic children
with bumetanide (Lemonnier et al., 2012), as well as the high inci-
dence of autism in Fragile X patients, Lemonnier and colleagues
used bumetanide to treat a child with Fragile X and concomi-
tant autistic diagnosis (Lemonnier et al., 2013). Interestingly,
after 3 months of treatment, the child achieved an improve-
ment in several clinical tests addressing autistic behavior and
intellectual disability. As this is a promising single case report,
further studies will have to evaluate the therapeutic potential
of bumetanide treatment for Fragile X on a larger cohort of
patients. This is in line with recent articles reporting that switch of
GABAergic transmission from depolarizing to hyperpolarizing is
delayed in Fmr1KO mice (He et al., 2014). Nevertheless, future
treatments of Fragile X adults with bumetanide, may require
further pre-clinical investigation because excitatory GABAergic
transmission seems to persist in the adult hippocampus whereas
inhibitory GABAergic transmission takes eventually over in
the cortex of Fmr1KO mice (He et al., 2014; Tyzio et al.,
2014).
RETT SYNDROME
Rett syndrome is a chromosome X-linked neurodevelopmental
disorder caused bymutations in theMethyl-CpG-binding protein
2 (MECP2) gene. Rett syndrome patients develop normally until
the age of 6–18 months, but then they undergo a developmental
regression that courses with loss of speech, motor coordination,
breathing abnormalities and cognitive impairment (Amir et al.,
1999; Leblanc and Fagiolini, 2011). Also, epilepsy is present in
80% of patients (Jian et al., 2006). As for the other neurode-
velopmental disorders described above, a number of evidence
in Rett syndrome patients point to alteration of GABAergic
transmission. Indeed, density of GABA receptors is increased
in young patients (Blue et al., 1999), and benzodiazepine bind-
ing to GABAAR is decreased in adult patients (Yamashita et al.,
1998). Interestingly, a recent study found KCC2 levels decreased
in cerebrospinal fluid (CSF) of Rett syndrome patients (Duarte
et al., 2013). Although these studies in patients point to a gen-
eral alteration in GABAergic signaling in Rett syndrome, whether
this alteration entails decreased or increased transmission is not
clear yet.
Experiments in MECP2 deficient mice also point to a general
impairment in the GABAergic system, with contrasting results
on whether GABAergic transmission is increased or decreased
depending on the brain area analyzed. In particular, in postnatal
ventro-lateral medulla decreased levels of α2 GABAAR subunit-
expression and a decrease in amplitude and frequency of sIPSCs
were described (Medrihan et al., 2008). Conversely, recordings
from layer V pyramidal neurons of olderMECP2KOmice showed
no change in mIPSCs (Dani et al., 2005). Moreover, MECP2 KO
mice present altered expression of VGAT in the thalamus with
decreased expression in the ventro-basal complex and increased
expression in the reticular thalamic nucleus accompanied by fre-
quencies of mIPSCs changing in the same direction (Zhang et al.,
2010). Finally, a decrease in GABA release has been also described
in MECP2 deficient mice (Medrihan et al., 2008; Jin et al., 2013).
A demonstration for a pivotal role for GABAergic system in
Rett syndrome was provided by a study that deleted MECP2
exclusively in GABAergic neurons (Chao et al., 2010). In this
mouse model, many of the Rett syndrome symptoms such as
increased stereotypical behaviors, progressive motor and respi-
ratory dysfunctions, alterations in social behavior and prema-
ture death were reproduced and the epileptic phenotype clearly
emerged. Accordingly, MECP2 is a regulator of gene transcription
highly expressed in GABAergic neurons (Akbarian et al., 2001),
and its deletion causes a decrease in mRNA levels of GAD65,
as well as in calbindin and calretinin, although an increase in
parvalbumin (Durand et al., 2012). Moreover, one of the tar-
gets of MECP2 is GABRB3 (Leblanc and Fagiolini, 2011). Finally,
also indirect findings in MECP2 deficient mice suggest a role for
GABA in the pathology of this disorder. Indeed, dark rearing,
an intervention which strongly affects GABAergic transmission
(Benevento et al., 1995; Lee et al., 2006a), was able to rescue
parvalbumin interneuron connectivity in the visual cortex and
visual acuity of MECP2 KO mice (Durand et al., 2012). Of note,
the respiratory alterations found in these mice were alleviated
by treatment with benzodiazepine Midazolam, further suggesting
the involvement of the GABAergic system in the general pathol-
ogy of Rett syndrome disorder (Voituron and Hilaire, 2011). Yet,
deletion of MECP2 exclusively in excitatory neurons has been
recently shown to lead to epileptic phenotype and reduction of
GABAergic synapses, indicating that MECP2 is also important in
these cells (Zhang et al., 2014).
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DOWN SYNDROME
Down syndrome (DS) is a genetic condition caused by the tri-
somy of the twenty first chromosome and it is the most common
genetic cause of intellectual disability accompanied in adult-
hood by Alzheimer-like pathology (Costa and Scott-McKean,
2013). Despite its relative frequency (i.e., 1 in 700 live births),
the molecular mechanisms that mediate it are largely unknown.
Nevertheless, several data from both patients and mouse models
of DS support the notion that alterations in GABAergic sig-
naling may underlie the cognitive component of this pathology
(Kleschevnikov et al., 2004; Fernandez et al., 2007; Chakrabarti
et al., 2010; Martinez-Cue et al., 2013). Indeed, GABA levels
are reduced in the fetal frontal cortex (Whittle et al., 2007)
and in the temporal lobes of children with DS (Smigielska-
Kuzia et al., 2010). Conversely, results from postmortem adult
brains are mostly unclear describing a decrease in the number
of calbindin and parvalbumin interneurons in cortex, but a non-
significant trend to reduced GABA in different brain regions,
possibly because experiments were performed on brains from
patients who had developed Alzheimer-like pathology (Reynolds
and Warner, 1988; Kobayashi et al., 1990; Seidl et al., 2001).
Additionally, a study with human neural progenitor cells found
increased α2 and decreased α5 and β3 GABAAR-subunit expres-
sion (Bhattacharyya et al., 2009). Thus, as for Rett syndrome,
studies on DS patients point to a general alteration in GABAergic
signaling, although it is not clear yet whether this alteration is due
to a decreased or an increased transmission.
To aid experimental investigation on DS, a number of mouse
models have been generated, and among those, the Ts65Dn is
the best characterized (Costa and Scott-McKean, 2013). Notably,
a large body of work has pointed to a role for increased
GABAergic transmission in these mice. First, a reorganization
of inhibitory synapses of granule cells in the dentate gyrus and
an increase in the number of calretinin, parvalbumin, somato-
statin and calbindin interneurons were observed in the cortex
(Belichenko et al., 2004; Chakrabarti et al., 2010; Perez-Cremades
et al., 2010). Accordingly, GABAergic markers such as GAD65,
GAD67, VGAT and gephyrin were elevated (Martinez-Cue et al.,
2013). Moreover, GABA release (Begenisic et al., 2014) and
evoked IPSCs of both GABAA and GABAB receptors were also
increased (Kleschevnikov et al., 2012), with some authors find-
ing increased GABAergic transmission particularly during the
second postnatal week (Mitra et al., 2012). As Belichenko and
coworkers found a decrease in β2/3 receptor at 3, but not at
8 months in the Ts65Dn model, this could indicate that not
only the receptor distribution, but also its expression during cer-
tain developmental windows could be relevant to the disease
(Belichenko et al., 2009b). Finally, Ts65Dn and Ts1Cje models
of DS, showed decreased LTP and increased LTD in the hip-
pocampus, which could be rescued by the use of GABAA antag-
onists (Siarey et al., 1999; Kleschevnikov et al., 2004; Costa and
Grybko, 2005; Belichenko et al., 2007, 2009a; Fernandez et al.,
2007). At the behavioral level, a number of treatments aimed
at decreasing GABAergic transmission have been attempted in
mouse models of DS with the aim of rescuing cognitive deficits.
In particular, Fernandez and colleagues treated Ts65Dn animals
with several GABAA antagonists (i.e., picrotoxin, bilobalide and
pentylenetetrazole) and observed an improvement in declarative
memory in the novel-object recognition and the spontaneous-
alternation tasks (Fernandez et al., 2007). Interestingly, 2-week
treatment with pentylenetetrazole maintained improved mem-
ory in the novel object recognition task up to 2 months after
treatment discontinuation. Furthermore, an independent study
showed that pentylenetetrazole was also able to rescue spatial
memory in the Morris water maze in Ts65Dn mice (Rueda et al.,
2008).
Unfortunately, chronic administration of GABAA antagonists
carries the risk of increasing seizure susceptibility. Thus, this
pharmacological approach may not be readily translated into
clinical practice because of the higher incidence of seizures that
characterizes DS patients (and mouse models; Westmark et al.,
2010; Rissman and Mobley, 2011). In the search of a better
pharmacological approach that would avoid the risk of further
increasing seizure susceptibility in DS, two independent groups
specifically targeted the α5 subunit of the GABAAR. α5 sub-
unit is highly expressed in the hippocampus (Sur et al., 1998)
and authors predicted that its antagonization would provide
enough disinhibition to rescue hippocampal-dependent mem-
ory. On the other hand, since α5 is not widely expressed in
other brain regions, authors also predicted that risk of seizure
induction would be less by a α5 subunit antagonist than by gen-
eral GABAAR antagonists. In particular, Braudeau and coworkers
found that treatment with an α5 inverse agonist rescued spatial
memory as well as object-recognition memory in Ts65Dn mice
(El Idrissi et al., 2005; Braudeau et al., 2011a,b; Potier et al.,
2014). Moreover, recent findings describe that treatment with a
negative allosteric modulator of α5 subunit-containing GABAARs
rescues spatial memory, Schaffer collateral LTP, GAD65, GAD67,
VGAT and gephyrin levels in Ts65Dn mice (Martinez-Cue et al.,
2013). Interestingly, this treatment also increases cellular prolif-
eration in the dentate gyrus (Martinez-Cue et al., 2013). This
could indicate restored adult neurogenesis, which is also affected
in DS models and partly responsible for the cognitive impair-
ment (Rueda et al., 2005; Clark et al., 2006; Ishihara et al., 2010;
Contestabile et al., 2013). Based on all of these studies, Hoffmann-
La Roche has recently completed a Phase 1 and started a Phase 2
clinical trial (NCT01436955, NCT02024789, http://clinicaltrials.
gov/) with an α5 inverse agonist aimed at measuring safety and
cognitive improvement in DS patients, but no results have been
posted yet.
Finally, also indirect evidence suggests that GABAergic treat-
ments may ameliorate DS symptoms. For example, treating
Ts65Dn pups with fluoxetine results in the normalization of a
number of anatomical defects in the dentate gyrus-CA3 region
of the hippocampus (Stagni et al., 2013), and treatment during
adulthood rescues hippocampal adult neurogenesis (Clark et al.,
2006). Since fluoxetine strongly and directly alters GABAergic
hippocampal neurotransmission independently of its effect on
amine reuptake systems (Mendez et al., 2012), it is tempting
to speculate that fluoxetine effect on DS may be mediated by
GABAergic transmission. Accordingly, a chronic treatment with
fluoxetine normalizes GABA release and promotes recovery of
cognitive impairment and hippocampal synaptic plasticity in
adult Ts65Dn mice (Begenisic et al., 2014).
Frontiers in Cellular Neuroscience www.frontiersin.org May 2014 | Volume 8 | Article 119 | 10
Deidda et al. Modulation of GABAergic transmission: pathophysiology
Thus, based on studies on animal models, treatment of DS
with drugs targeting GABAergic transmission seems a promis-
ing venue. Nevertheless, in the context of finding GABAergic
treatment for DS with reduced side effects, it will be essential to
investigate the mechanisms involved in increased seizure preva-
lence in both humans and mouse models (Pueschel et al., 1991;
Westmark et al., 2010).
SCHIZOPHRENIA
Schizophrenia is a neurodevelopmental disorder characterized
by psychosis and cognitive deficits (Lewis et al., 2012). Multiple
evidence shows that GABA plays a role in the development of
schizophrenia by affecting mostly (but not only) cognitive aspects
of the disorder (Ahn et al., 2011; Gonzalez-Burgos et al., 2011).
Indeed, alterations in most domains of GABA-signaling have
been described in schizophrenic patients. For example, varia-
tions in the GAD1 gene can increase risk of schizophrenia, and
schizophrenic patients who carry a single nucleotide polymor-
phism in this gene have increased GAD25/GAD67 ratios in the
hippocampus, suggesting that an immature GABAergic system
is retained (Hyde et al., 2011). Moreover, GAD67, GAD65, and
reelin (a protein mainly secreted by GABAergic interneurons)
mRNAs and proteins are decreased in a number of brain regions,
including the prefrontal cortex and cerebellum of schizophrenic
patients (Guidotti et al., 2000; Fatemi et al., 2005; Hashimoto
et al., 2008). These reductions are also observed in rodent mod-
els of schizophrenia. For example, chronic stimulation of D2
dopaminergic receptors reduces GAD67 expression (Schmidt and
Mirnics, 2012), NMDA-receptor antagonism by phencyclidine
(PCP) reducesmRNA levels of GAD65 andGAD67 (Bullock et al.,
2009), isolation of rats leads to a decrease in reelin protein as well
as number of reelin-positive cells in the dentate gyrus (Cassidy
et al., 2010), and neonatal ventral hippocampus lesions decrease
GAD67 mRNA in adult rats, an effect that can be counteracted by
antipsychotic treatments (Lipska et al., 2003).
Specific alterations to GABAergic interneurons such as a
decrease in the density of calbindin interneurons of the ante-
rior cingulate cortex (Cotter et al., 2002) and a decrease in
mRNA for markers of different interneuron subpopulations (i.e.,
somatostatin, parvalbumin and cholecystokinin) across differ-
ent regions have been also described in schizophrenic patients
(Hashimoto et al., 2008; Fung et al., 2010). Interestingly, par-
valbumin downregulation is also common to genetic (Erbb4,
DISC1) and non-genetic (PCP treatment, methylazoxymethanol
administration during gestation, isolation) rodent and primate
models (PCP-treatment; Cochran et al., 2003; Harte et al., 2007;
Hikida et al., 2007; Morrow et al., 2007; Fisahn et al., 2009).
In particular, deletion of Erbb4 from fast-spiking interneurons
in mice leads to a decrease in GAD67 and parvalbumin protein
levels, aberrant neuronal excitability and behavioral abnormali-
ties (impairment in working memory, sociability and pre-pulse
inhibition), consistent with a schizophrenic phenotype (Del Pino
et al., 2013). Moreover, chandelier interneuron terminals in the
prefrontal cortex of patients show a decreased GAT1 expres-
sion (Woo et al., 1998; Pierri et al., 1999), and GAT1 mRNA
is decreased in cerebellum of PCP-treated rats with GAT1 pos-
itive chandelier interneuron cartridges decreased in the cortex
of isolated rats (Bloomfield et al., 2008; Bullock et al., 2009).
Taking advantage of this knowledge, Yu and colleagues explored
the behavioral phenotype of GAT1 KO mice, and concluded it
could be used as a model of schizophrenia (Yu et al., 2013).
Although the above described results onGAD and on the different
subpopulations of interneurons in schizophrenia would predict a
net decrease in GABA production, measurements of total GABA
in brains of patients by magnetic resonance spectroscopy (MRS)
are conflicting, describing both a decrease and an increase (Goto
et al., 2009; Ongur et al., 2010; Yoon et al., 2010).
Alterations in different GABAAR subunits were also reported
in schizophrenic patients, including decrease in mRNA for α1,
α5, β2, δ, and θ subunits and increase in α2 and ρ2, subunits
(Volk et al., 2002; Hashimoto et al., 2008; Beneyto et al., 2011;
Fatemi et al., 2013). On the other hand, increased mRNA lev-
els of α1, α6, β2, β3, and δ, as well as GABAAR binding have
been described in animal models (Endo et al., 2007; Bullock
et al., 2009). A postmortem study showing increased GABAAR
binding in the prefrontal cortex of schizophrenic patients further
adds to the theory of disrupted GABAergic activity in this disor-
der (Benes et al., 1996). Thus, from this experimental evidence
GABAergic transmission appears either increased or decreased
in schizophrenic patients and animal models, depending on the
brain area.
Interestingly, benzodiazepine treatment (alone or in combina-
tion with antipsychotics) has been used with mixed results for
the treatment of anxiety and management of psychotic symp-
toms in schizophrenia. Nevertheless, 30–50% of patients respond
favorably, possibly suggesting that GABA alterations are present
in some patients, but not in others (Wolkowitz and Pickar, 1991).
Data showing that antagonism of GABAARs by iomazenil treat-
ment increases psychosis in only 50% of schizophrenics (and not
in healthy controls) further strengthen this hypothesis (Ahn et al.,
2011). To take advantage of this seeming therapeutic opportu-
nity, Lewis and colleagues performed a first clinical trial using a
benzodiazepine-like drug with specificity for receptors contain-
ing α2 and α3 subunits, thus avoiding α1 and α5, which are mostly
involved in the side effects of conventional benzodiazepines. This
study showed improved delayed memory in the in schizophrenic
patients (Lewis et al., 2008). Nevertheless, a latter study did not
find any improvement using the same compound in a larger
sample of patients (Buchanan et al., 2011). As discussed above,
the difference may rest in the fact that the impairment of the
GABAergic signaling may be present only in a subpopulation of
patients.
Finally, also factors that influence [Cl−]i concentration have
been implicated in schizophrenia. For instance, the SLC12A2
gene, which encodes for NKCC1, has been reported to be a sus-
ceptibility gene for schizophrenia (Potkin et al., 2009). Notably,
Kim and colleagues found that an interaction between a sin-
gle nucleotide polymorphism in the SLC12A2 gene and a single
nucleotide polymorphism in the Disrupted in schizophrenia 1
(DISC1) gene increased risk for the development of schizophre-
nia (Kim et al., 2012). Moreover, KCC2 mRNA was decreased
together with increased NKCC1/KCC2 ratios in hippocampus of
patients (Hyde et al., 2011). Interestingly, the same group has
recently reported differential expression of NKCC1 splice variants
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and an increase of a new transcript variant of the KCC2 gene
in schizophrenia patients (Tao et al., 2012; Morita et al., 2014).
Finally, although expression of NKCC1 and KCC2 mRNA was
found unaltered in a study on prefrontal cortex of schizophrenic
patients, the same study found increased expression of OXSR1
and WNK3 transcripts, which act posttranscriptionally to up-
regulate NKCC1 and downregulate KCC2 activity (Arion and
Lewis, 2011).
TOURETTE SYNDROME
Tourette Syndrome (TS) is a neurodevelopmental disorder char-
acterized by the presence of movement and vocalization tics.
It is often comorbid with obsessive compulsive behavior, anxi-
ety, attention deficit hyperactivity disorder and sleep disorders
(Jankovic, 2001; McNaught and Mink, 2011). It also presents
with a higher incidence of epilepsy (Williams et al., 2013). As for
the other neurodevelopmental disorders described above, these
symptoms suggest an altered neuronal excitatory/inhibitory ratio,
with a possible implication of GABAergic signaling. Accordingly,
postmortem staining of basal ganglia of TS patients revealed a
decrease in the number of parvalbumin (PV) interneurons in the
caudate and putamen as well as an increase in the same popu-
lation in the globus pallidus pars interna (Kalanithi et al., 2005;
Kataoka et al., 2010). Furthermore, a recent study on GABAAR
binding in TS patients has shown a decreased in several regions
(i.e., ventral caudate, putamen, nucleus acumbens and globus pal-
lidus) and increase in others (i.e., substancia nigra, cerebellum
and left periaductal gray; Lerner et al., 2012). Moreover, a recent
genetic study found a correlation between severity of symptoms
and increased blood expression of GABAAR subunit α2–4, β1, ρ1,
and GABAAR-associated protein in patients (Tian et al., 2011).
The same study also showed that genes encoding for the α4 and
γ1 GABAAR subunits presented alternative splicing (Tian et al.,
2011). Further strengthening the idea of an implication of the
GABAergic system in TS is the fact thatmicroinjections of GABAA
antagonists into the striatum of both mice and primates induce
motor tics resembling those of Tourette patients (McCairn et al.,
2009; Worbe et al., 2009; Bronfeld et al., 2013). Furthermore,
pharmacological blockade of fast-spiking interneurons in the
striatum is sufficient alone to elicit movement abnormalities also
resembling those of TS (Gittis et al., 2011). Finally, there is some
clinical evidence of GABAergic drugs being useful to control tics.
In particular, clonazepam and levetiracetam have shown a mod-
est profile in tic suppression, although more double-blind trials
are needed to draw definitive conclusions (Shprecher and Kurlan,
2009; Martinez-Granero et al., 2010).
NEUROFIBROMATOSIS TYPE 1
Neurofibromatosis type 1 is a genetic disorder caused by muta-
tions in the NF1 gene. The phenotype is not homogeneous, and
it includes presence of neurofibromas, cognitive impairment and
increased epilepsy (Costa and Silva, 2002; Diggs-Andrews and
Gutmann, 2013; Ostendorf et al., 2013). Increased hyperactivity,
sleep disturbance, and emotional issues are also present (Johnson
et al., 2005; Leschziner et al., 2013).
Both evidence in patients and studies in the NF1 KO mouse
model of neurofibromatosis type 1 point to defects in GABAergic
transmission, although with contrasting results. A recent study
used MRS to measure total GABA in the visual cortex of NF1
patients and found that its level was decreased in compari-
son to controls (Violante et al., 2013). Conversely, work with
NF1 mutant mice showed an increased GABA release as well as
GABAergic transmission, and hypothesized them to be a cause
for cognitive impairment (Costa et al., 2002; Cui et al., 2008;
Shilyansky et al., 2010). In particular, NF1 KO mice showed an
increase in the amplitude of evoked IPSPs, in the frequency of
spontaneous IPSCs, and in the frequency of miniature IPSCs
when measured in high potassium medium (Costa et al., 2002;
Cui et al., 2008; Shilyansky et al., 2010). Cui and colleagues also
observed that the increase in frequency of the miniature IPSCs
was still present when the NF1 mutation was induced exclusively
in interneurons, but not when it was only present in pyramidal
neurons, again pointing to a key role of GABAergic transmis-
sion in the disease (Cui et al., 2008). Interestingly, NF1 KO mice
also show deficits in CA1hippocampal LTP, spatial learning and
working memory that can be reverted by the GABAA antagonist
picrotoxin (Costa et al., 2002; Cui et al., 2008; Shilyansky et al.,
2010).
SUCCINIC SEMIALDEHYDE DEHYDROHENASE DEFICIENCY, TUBEROUS
SCLEROSIS COMPLEX, ANGELMAN SYNDROME, PRADER-WILLI
SYNDROME
Although less frequent and less studied, other neurodevelop-
mental disorders have also been related to defective GABAergic
transmission.
Succinic semialdehyde dehydrohenase deficiency (SSDHD) is
caused by a deficit of the GABA catabolitic enzyme succinic
semialdehyde dehydrohenase and it thus results in an increase
of GABA and γ-hydroxybutiryc acid (GHB, a by-product of
GABA catabolism). The disorder courses withmental retardation,
autistic-like behavior, hypotonia and seizures (Pearl et al., 2011;
Vogel et al., 2013).
Tuberous sclerosis complex (TSC) is caused by loss of function
of TSC1 and TSC2 genes, and courses with presence of corti-
cal tubers, mental retardation, autistic-like behavior and epilepsy.
Interestingly, studies of the tubers have shown decreased expres-
sion of GABAAR α1 subunit, decreased benzodiazepine-receptor
binding and decreased expression of KCC2, as well as increased
GABA levels and increased expression of NKCC1 (Talos et al.,
2012). Interestingly, treatment with vigabatrin (an inhibitor of
GABA-T) improves cognitive and behavioral issues and it is
effective for controlling seizures in TSC (Jambaque et al., 2000).
Angelman and the closely related Prader-Willi Syndromes, are
the result of deletion/methylation of chromosome region15q11–
13. If the mutation is of maternal origin, it will give rise to
Angelman Syndrome, whereas if the mutation is of paternal ori-
gin, the result will be Prader-Willi Syndrome (Zafeiriou et al.,
2013). Interestingly, although considered distinct pathologies,
both disorders share symptoms such as mental retardation and
autism-like behaviors, and Angelman Syndrome patients are at
higher risk of developing seizures (Buiting, 2010; Zafeiriou et al.,
2013). Since the chromosomal region involved in these two dis-
orders contains the genes of three GABAAR subunits (i.e., α5,β3,
and γ3; Fiumara et al., 2010), this may indicate an involvement of
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the GABAergic system, as confirmed by some studies suggesting
abnormal GABA metabolism in these disorders (Dhossche et al.,
2005).
GABAergic THERAPIES: TOWARD INNOVATION AND
BEYOND
Neurodevelopmental disorders are a number of heterogeneous
conditions that share a strong social and emotional impact on
the lives of patients and their families. Although their etiology
is very different and they are characterized by a variety of clini-
cal pictures, they surprisingly share a large number of symptoms
such as cognitive impairment, increased seizure susceptibility and
sleep disturbance. Interestingly, an excitatory/inhibitory imbal-
ance in neuronal activity -at least partly due to a disruption in
the GABAergic system- also appears as a common feature to most
of these pathologies.
From a historical point of view, research aimed to develop
therapeutic strategies mostly addressing either GABAAR func-
tion or GABAmetabolism, possibly because it simply represented
the more intuitive approach. For example, in a number of stud-
ies researchers directly targeted GABA signaling by treatment
of animal models with GABAA agonists (i.e., autism, Fragile X,
Rett syndrome; Olmos-Serrano et al., 2011; Voituron and Hilaire,
2011; Han et al., 2012) or antagonists (i.e., Down syndrome
and Neurofibromatosis type I; Fernandez et al., 2007; Cui et al.,
2008). Although encouraging results indicate improvement of
both cognitive and non-cognitive symptoms in these models, it
is important to be cautious when translating data from animal
models to humans. For example, certain apparent discrepancies
between animal models of the diseases and patients such as those
described for Down syndrome, Rett syndrome, schizophrenia,
and Neurofibromatosis type 1 have to be properly addressed,
possibly through parallel studies in animals and humans by the
same researchers with similar experimental approaches, when
achievable.
Since most discussed developmental disorders present
increased risk of epileptic seizures, adequate controls for seizure
activity should be performed. Furthermore, since GABA is a very
widespread neurotransmitter acting both at the CNS and PNS
levels and in a number of periphery organs (Roberts and Krause,
1982; Watanabe et al., 2002), treatments with GABAA antagonists
could lead to excessive disinhibition through the blocking of
both phasic and shunting inhibition and treatment with GABAA
agonists can lead to undesired side effects such as drowsiness and
muscle relaxation (Rudolph et al., 1999; Griebel and Holmes,
2013). Thus, issues on the potentials of translating experimental
findings into the clinical practice, forced researchers to find more
subtle ways to modulate GABAergic transmission. The discovery
that different GABAAR subunits finely modulate GABAergic
responses in physiology (e.g., tonic vs. phasic inhibition) inspired
researchers to target specific subunits in neurodevelopmental
disorders to reduce side effects of GABAAergic pharmacological
treatments (e.g., the specific antagonists of the α5 subunit in the
Ts65Dn animal model of Down syndrome to recover cognitive
deficits without pro-epileptic side effects; Braudeau et al.,
2011b; Martinez-Cue et al., 2013). In addition, GABAA agonists
selective for the α2,3 subunits are being researched as potential
anxiolytic/analgesic drugs that lack the sedative effects, which
are mainly mediated by α1 (Mohler, 2011), and these drugs are
also being tested for schizophrenia (Lewis et al., 2008; Buchanan
et al., 2011; Mohler, 2011). Moreover, it has been recently
argued that drugs acting on the GABAA δ subunit can aid the
treatment of Fragile X (Hagerman et al., 2009; Olmos-Serrano
et al., 2011; Heulens et al., 2012). Given the latter encouraging
results, it is possible that future therapies -if aimed at targeting
GABAAR subunits specifically affected in the diverse diseases-
will present even further reduced side effects by restoring proper
brain function with no effect on other “non-diseased” receptors.
However, further research focusing on alteration of specific
GABAA subunits in each different neurodevelopmental disorder
and further research focusing on developing drugs that selectively
act on these specific subunits are a prerequisite before treatment
implementation (Mohler, 2011).
The discovery that action of NKCC1/KCC2 could indirectly
modulate GABAergic transmission opened new avenue for thera-
peutic research readably translatable into clinical trials. First, high
expression of NKCC1 in the neonatal brain was suggested to be a
concomitant cause aggravating epilepsy in infants (Dzhala et al.,
2005). Then, modulation of GABAergic transmission trough vari-
ation in the activity of cation/Cl− cotransporters was described
under particular physiological conditions (e.g., delivery and
adult neurogenesis) and in neurodevelopmental disorders (e.g.,
Fragile X, Rett syndrome, schizophrenia). As NKCC1 inhibitor
bumetanide is an FDA-approved loop diuretic extensively used
in the past with very mild side effects (Kahle and Staley, 2008),
clinicians were readily allowed to perform clinical trials on the
use of bumetanide to treat infant and adult epilepsy, and more
recently autism in young patients with encouraging results (Kahle
et al., 2009; Lemonnier and Ben-Ari, 2010; Lemonnier et al., 2012;
Eftekhari et al., 2013; Hadjikhani et al., 2013). As neurodevelop-
mental disorders are characterized by increased susceptibility to
seizures, diuretic treatment seems a very promising approach also
because loop diuretics have been clinically tested in the past as
antiepileptics by a mechanism proposed to be independent from
GABAergic transmission (Maa et al., 2011). Indeed, bumetanide
decreases cell volume and increases the extracellular space, both
of which contribute to decrease neuronal excitability and syn-
chrony of neuronal network by means of the so called “ephaptic
effect,” namely a synapse-independent form of propagation of
electrical signals (Haglund and Hochman, 2005; Maa et al., 2011;
Hochman, 2012). Moreover, action on cation chloride cotrans-
porters is predicted to be a subtler approach with milder side
effects than direct action on GABAARs by agonists/antagonists as
shunting inhibition (which critically depends on the number of
open GABAARs) results only slightly affected by small changes
in [Cl−]i. Nevertheless, as bumetanide does not pass well the
blood-brain barrier (BBB) in mice, more lipophylic bumetanide
prodrugs are being developed to address this issue, while avoid-
ing the diuretic effect due to bumetanide action on NKCC2, an
isoform present in the kidney. Some of these drugs have recently
been tested in rodents and seem to have better brain penetration
(Loscher et al., 2013; Tollner et al., 2014).On the other hand, a
completely new compound (CLP257) was very recently described
to restore Cl− balance by increasing KCC2 expression at the
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plasma membrane and it was able to rescue nociceptive responses
in a rat model of neuropathic pain, providing a new and efficient
tool to tackle hyperexcitability in the SNC (Gagnon et al., 2013).
Finally, also environmental enrichment (EE), which exerts
a profound influence over GABAergic transmission (Cancedda
et al., 2004; Sale et al., 2010) results in behavioral, synaptic
and connectivity rescues in models of neurodevelopmental disor-
ders (Restivo et al., 2005; Nithianantharajah and Hannan, 2006;
Lonetti et al., 2010; Begenisic et al., 2011; Durand et al., 2012;
Hannan, 2014), and could thus be considered a possible thera-
peutic approach. In particular, EE rescues spatial memory and
dentate gyrus LTP as well as neuronal proliferation in Ts65Dn ani-
mals (Begenisic et al., 2011; Chakrabarti et al., 2011). Moreover,
cortical LTP, anxiety behavior, motor coordination and spatial
learning could be rescued in MECP2 null mice by EE (Kondo
et al., 2008; Nag et al., 2009; Kerr et al., 2010; Lonetti et al.,
2010) with an indication that the inhibitory GABAergic system
could be preferentially responsible for the effect (Boggio et al.,
2010; Lonetti et al., 2010). Furthermore, EE restored environment
exploration and dendritic branching/length in Fmr1KO mice
(Restivo et al., 2005), and it was able to ameliorate some symp-
toms in a genetic model of schizophrenia (McOmish et al., 2008).
Finally, behavioral impairments such as nociception, motor coor-
dination, pre-pulse inhibition, stereotyped behavior, grooming,
memory deficits, anxiety, social deficits were rescued in a number
of mice models of ASD reared in an EE (Schneider et al., 2006;
Lacaria et al., 2012; Reynolds et al., 2013). Although EE does seem
ideal as a non-invasive treatment, there is however controversy
as to how well it will translate to the human setting, given that
some of the effects that are sometimes reported in environmen-
tally enriched animals could be just considered as the rescue of the
environmental deprivation of the standard housing conditions of
laboratory animals (Nithianantharajah and Hannan, 2006; Sale
et al., 2014). Nevertheless, the first recent attempts to translate EE
into the humans setting have proven useful for the treatment of
autism (Woo and Leon, 2013).
CONCLUDING REMARKS
In conclusion, we reviewed that modulation of GABAergic trans-
mission plays a pivotal role in regulating brain activity under
physiological conditions during development, and disruption of
GABAergic signaling is a hallmark of many neurodevelopmen-
tal disorders. Thus, correcting GABA signaling in pathological
conditions could reinstate physiological level of brain function
in a pathological background. On the other hand, because of
the complex role for GABA in regulating physiological neuronal
activity during development and in adulthood, careful consid-
eration should be paid in the treatment of neurodevelopmental
disorders by GABAergic therapies to decrease side effects. We
propose that further dissection of the molecular mechanisms in
place for the regulation of brain development under physiolog-
ical conditions may inspire researchers to address GABAergic
transmission with a subtle and physiological approach also in
neurodevelopmental disorders. Moreover, a detailed study of the
specific defects in GABAergic transmission in the different neu-
rodevelopmental disorders must be achieved before being able to
design the best therapeutic strategies. Also, it will be compulsory
to perform thorough research on humans as data in animal mod-
els are at times not paralleled by findings in humans. In the near
future, studies with human-derived induced pluripotent stem
(iPS) cells will greatly aid to resolve this issue, by unraveling the
fine molecular pathways affected in each disorder in humans.
Indeed, cell lines derived from human patients are already avail-
able for mutations related to ASD such as SHANK3, as well as
for Fragile X, Rett syndrome, Down syndrome, and schizophrenia
(Marchetto et al., 2010; Urbach et al., 2010; Brennand et al., 2011;
Li et al., 2012). Thus, basic research on the role of GABAergic
transmission during physiological and pathological brain devel-
opment is a fundamental prerequisite in the design of innovative
pharmacological treatments with reduced side effects.
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